Ryan D Maynard - Net Worth and Insider Trading
Ryan D Maynard Net Worth
The estimated net worth of Ryan D Maynard is at least $64,684 dollars as of 2026-09-11. Ryan D Maynard is the Director of Iovance Biotherapeutics Inc and owns about 7,500 shares of Iovance Biotherapeutics Inc (IOVA) stock worth over $61,125. Ryan D Maynard is the CHIEF FINANCIAL OFFICER of Cara Therapeutics Inc and owns about 223 shares of Cara Therapeutics Inc (CARA) stock worth over $3,559. Ryan D Maynard is also the EVP & CFO of Rigel Pharmaceuticals Inc and owns about 0 shares of Rigel Pharmaceuticals Inc (RIGL) stock worth over $0. Details can be seen in Ryan D Maynard's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Ryan D Maynard has not made any transactions after 2024-11-12 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Ryan D Maynard
Ryan D Maynard Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Ryan D Maynard owns 5 companies in total, including Iovance Biotherapeutics Inc (IOVA) , Rigel Pharmaceuticals Inc (RIGL) , and Cara Therapeutics Inc (CARA) among others .
Click here to see the complete history of Ryan D Maynard’s form 4 insider trades.
Insider Ownership Summary of Ryan D Maynard
| Ticker | Company | Transaction Date | Type of Owner |
|---|---|---|---|
| IOVA | Iovance Biotherapeutics Inc | 2024-11-12 | director |
| RIGL | Rigel Pharmaceuticals Inc | 2017-11-03 | VP Finance & Acting CFO |
| CARA | Cara Therapeutics Inc | 2023-02-08 | Chief Financial Officer |
 | | 2022-09-12 | Chief Financial Officer |
| | 2026-02-23 | Chief Financial Officer |
Ryan D Maynard Latest Holdings Summary
Ryan D Maynard currently owns a total of 3 stocks. Among these stocks, Ryan D Maynard owns 7,500 shares of Iovance Biotherapeutics Inc (IOVA) as of November 12, 2024, with a value of $61,125 and a weighting of 94.5%. Ryan D Maynard owns 223 shares of Cara Therapeutics Inc (CARA) as of February 8, 2023, with a value of $3,559 and a weighting of 5.5%. Ryan D Maynard also owns 0 shares of Rigel Pharmaceuticals Inc (RIGL) as of November 3, 2017, with a value of $0 and a weighting of 0%.
Latest Holdings of Ryan D Maynard
| Ticker | Company | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| IOVA | Iovance Biotherapeutics Inc | 2024-11-12 | 7,500 | 8.15 | 61,125 |
| CARA | Cara Therapeutics Inc | 2023-02-08 | 223 | 15.96 | 3,559 |
| RIGL | Rigel Pharmaceuticals Inc | 2017-11-03 | 0 | 47.28 | 0 |
Holding Weightings of Ryan D Maynard
Ryan D Maynard Form 4 Trading Tracker
According to the SEC Form 4 filings, Ryan D Maynard has made a total of 2 transactions in Iovance Biotherapeutics Inc (IOVA) over the past 5 years, including 1 buys and 1 sells. The most-recent trade in Iovance Biotherapeutics Inc is the sale of 50,000 shares on November 12, 2024, which brought Ryan D Maynard around $503,000.
According to the SEC Form 4 filings, Ryan D Maynard has made a total of 1 transactions in Cara Therapeutics Inc (CARA) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Cara Therapeutics Inc is the sale of 152 shares on February 8, 2023, which brought Ryan D Maynard around $2,909.
According to the SEC Form 4 filings, Ryan D Maynard has made a total of 0 transactions in Rigel Pharmaceuticals Inc (RIGL) over the past 5 years. The most-recent trade in Rigel Pharmaceuticals Inc is the sale of 10,000 shares on November 3, 2017, which brought Ryan D Maynard around $390,000.
Insider Trading History of Ryan D Maynard
* The information on this page (including Insider Trading Shares, Share Changes, Cost, etc.) is sourced exclusively from Form 4 filings and does not incorporate any data from 13F or 13D/G filings. As a result, it may differ from the values shown on the Guru page.
- 1
Ryan D Maynard Trading Performance
GuruFocus tracks the stock performance after each of Ryan D Maynard's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Ryan D Maynard is 58.81%. GuruFocus also compares Ryan D Maynard's trading performance to market benchmark return within the same time period. The performance of stocks bought by Ryan D Maynard within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Ryan D Maynard's insider trading performs compared to the benchmark.
Performance of Ryan D Maynard
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 69.93 | | | | | |
| Relative Return to S&P 500(%) | 77.36 | | | | | |
Ryan D Maynard Ownership Network
Ownership Network List of Ryan D Maynard
Ownership Network Relation of Ryan D Maynard
Ryan D Maynard Owned Company Details
What does Iovance Biotherapeutics Inc do?
Who are the key executives at Iovance Biotherapeutics Inc?
Ryan D Maynard is the director of Iovance Biotherapeutics Inc. Other key executives at Iovance Biotherapeutics Inc include Chief Financial Officer Roche Corleen M. , SVP & Finance (Int. PFO & PAO) Matthew W. Rosinack , and General Counsel Frederick G Vogt .
Iovance Biotherapeutics Inc (IOVA) Insider Trades Summary
Over the past 18 months, Ryan D Maynard made no insider transaction in Iovance Biotherapeutics Inc (IOVA). Other recent insider transactions involving Iovance Biotherapeutics Inc (IOVA) include a net purchase of 30,000 shares made by Daniel Gordon Kirby , a net purchase of 25,000 shares made by Frederick G Vogt , and a net purchase of 5,600 shares made by Raj K. Puri .
In summary, during the past 3 months, insiders sold 0 shares of Iovance Biotherapeutics Inc (IOVA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Iovance Biotherapeutics Inc (IOVA) were sold and 60,600 shares were bought by its insiders, resulting in a net purchase of 60,600 shares.
Iovance Biotherapeutics Inc (IOVA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Iovance Biotherapeutics Inc Insider Transactions
Ryan D Maynard Mailing Address
Above is the net worth, insider trading, and ownership report for Ryan D Maynard. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Ryan D Maynard's mailing address is: San Carlos Ca 94070.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
